Phio Pharmaceuticals (United States)
Phio Pharmaceuticals Corporation is a US clinical stage biotechnology company developing its INTASYL siRNA in immuno-oncology. Formerly known as RXi Pharmaceuticals, the company's name was changed to Phio Pharmaceuticals in 2018. Derived from Wikipedia licensed CC-BY-SA.
Open Access statistics for Phio Pharmaceuticals (United States), United States, covering academic research published from 2009 to 2024. Read More.
Open Access Percentage
63%
Total
Publications
60
Total Open
Publications
38
Total
Citations
878
Open Access
Percentage
63%
Total
Publications
60
Total Open
Publications
38
Total
Citations
878
Breakdown
Publisher Open
47%
Both
12%
Other Platform Open
5%
Closed
36%
Percentage of Open Access over time
Publisher Open
Both
Other Platform Open
Closed
Volume of Open Access over time
Open
Closed
Publisher Open
OA Journal 14%
5
Hybrid 46%
16
No Guarantees 40%
14
Other Platform Open
Domain 100%
10
Institution 10%
1
Public 10%
1
Preprint 0%
0
Other Internet 0%
0
Other Platform Locations
Name | Platform Type | Publications |
|---|---|---|
PubMed Central | Domain | 10 |
Europe PMC | Domain | 6 |
University of Massachusetts Medical School - eScholarship@UMMS | Institution | 2 |
Semantic Scholar | Public | 1 |